Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2719 results

Sort By:

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Study ID: NCT07042295
Start Date: 2025-12-22
End Date: 2029-02-28
Study Type

Interventional

Study Phase

Phase2

No. of Participants

86

Intervention / Treatment

Amivantamab and Recombinant Human Hyaluronidase

Biospecimen Collection

Cetuximab

Computed Tomography

Magnetic Resonance Imaging

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Study ID: NCT06871410
Start Date: 2025-11-15
End Date: 2028-04-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

26

Intervention / Treatment

Autologous Anti-CD83 CAR T-cells

Biospecimen Collection

Chest Radiography

Computed Tomography

Cyclophosphamide

Echocardiography

Fludarabine Phosphate

Hydroxyurea

Leukapheresis

Lumbar Puncture

Positron Emission Tomography

Administration Questionnaire

Sponsor

Roswell Park Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Little NIRVANA for Pediatric Pain and Anxiety

Study ID: NCT06795126
Start Date: 2025-12-01
End Date: 2026-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

130

Intervention / Treatment

Little NIRVANA

Sponsor

Nationwide Children's Hospital

Source: clinicaltrials.gov

Share:
Add to list

Targeted Temperature Management at 33°C Versus Controlled Normothermia for In-hospital Cardiac Arrest

Study ID: NCT07086703
Start Date: 2025-12-01
End Date: 2029-05-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

788

Intervention / Treatment

Induced hypothermia at 33°C

Control normothermia

Sponsor

Nantes University Hospital

Source: clinicaltrials.gov

Share:
Add to list

Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study

Study ID: NCT07151456
Start Date: 2026-01
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase4

No. of Participants

224

Intervention / Treatment

Conventional 24-week glucocorticoid regimen

short-term course (12 week) glucocorticoid regimen

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Source: clinicaltrials.gov

Share:
Add to list

Basal Cell Carcinoma Chemoprevention Trial

Study ID: NCT05212246
Start Date: 2026-01-01
End Date: 2032-01-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1630

Intervention / Treatment

5% Imiquimod cream

Placebo Vehicle Control Cream

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body

Study ID: NCT07215260
Start Date: 2025-11-04
End Date: 2025-12-22
Study Type

Interventional

Study Phase

Phase1

No. of Participants

14

Intervention / Treatment

BI 3000202

Rosuvastatin

Digoxin

Sponsor

Boehringer Ingelheim

Source: clinicaltrials.gov

Share:
Add to list

Promoting Maintenance of Change Following Brief Intervention for Alcohol Use

Study ID: NCT05712382
Start Date: 2026-09
End Date: 2027-05
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

160

Intervention / Treatment

Parent handbook

Coping with negative emotions

Problem-solving risky situations

Recovering from slips

Sponsor

University of Massachusetts, Amherst

Source: clinicaltrials.gov

Share:
Add to list

Better Options for Lymphatic Filariasis Treatment

Study ID: NCT07159373
Start Date: 2026-03
End Date: 2028-06
Study Type

Interventional

Study Phase

Phase3

No. of Participants

5100

Intervention / Treatment

MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole

IDA - Ivermectin + DEC + albendazole

Sponsor

Medicines Development for Global Health

Source: clinicaltrials.gov

Share:
Add to list

A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients

Study ID: NCT07052994
Start Date: 2025-12-01
End Date: 2034-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

32

Intervention / Treatment

Revumenib

Cytrabine

Daunorubicin

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list